The Experts below are selected from a list of 297 Experts worldwide ranked by ideXlab platform

Amy S. Paller - One of the best experts on this subject based on the ideXlab platform.

  • topical calcipotriene for morphea Linear Scleroderma
    Journal of The American Academy of Dermatology, 1998
    Co-Authors: Bari B. Cunningham, Ian Landells, Craig B. Langman, Dawn Sailer, Amy S. Paller
    Abstract:

    Abstract Background: Morphea and Linear Scleroderma are characterized by erythema, induration, telangiectasia, and dyspigmentation. There is no universally effective treatment. Oral calcitriol has been beneficial in the treatment of localized and extensive morphea/Scleroderma, but the use of topical calcipotriene has not been reported. Objective: The purpose of this study was to evaluate the efficacy and safety of topical calcipotriene 0.005% ointment in the treatment of localized Scleroderma. Methods: In a 3-month open-label study, 12 patients aged 12 to 38 years with biopsy-documented active morphea or Linear Scleroderma applied calcipotriene ointment under occlusion twice daily to plaques for 3 months. The condition of each patient had previously failed to respond to potent topical corticosteroids and, for some patients, systemic medications. Efficacy was assessed at baseline, 1 month, and 3 months. Levels of serum ionized calcium, intact parathyroid hormone, and 1,25-dihydroxyvitamin D and of random urinary calcium excretion were measured. Results: During the 3-month trial, the condition of all 12 patients showed statistically significant improvement in all studied features. No adverse effects were reported or detected through laboratory monitoring of mineral metabolism. Conclusion: Topical calcipotriene 0.005% ointment may be an effective treatment for localized Scleroderma, but double-blind placebo controlled studies are needed for confirmation. (J Am Acad Dermatol 1998;39:211-5.)

  • Topical calcipotriene for morphea/Linear Scleroderma.
    Journal of the American Academy of Dermatology, 1998
    Co-Authors: Bari B. Cunningham, Ian Landells, Craig B. Langman, Dawn E. Sailer, Amy S. Paller
    Abstract:

    Abstract Background: Morphea and Linear Scleroderma are characterized by erythema, induration, telangiectasia, and dyspigmentation. There is no universally effective treatment. Oral calcitriol has been beneficial in the treatment of localized and extensive morphea/Scleroderma, but the use of topical calcipotriene has not been reported. Objective: The purpose of this study was to evaluate the efficacy and safety of topical calcipotriene 0.005% ointment in the treatment of localized Scleroderma. Methods: In a 3-month open-label study, 12 patients aged 12 to 38 years with biopsy-documented active morphea or Linear Scleroderma applied calcipotriene ointment under occlusion twice daily to plaques for 3 months. The condition of each patient had previously failed to respond to potent topical corticosteroids and, for some patients, systemic medications. Efficacy was assessed at baseline, 1 month, and 3 months. Levels of serum ionized calcium, intact parathyroid hormone, and 1,25-dihydroxyvitamin D and of random urinary calcium excretion were measured. Results: During the 3-month trial, the condition of all 12 patients showed statistically significant improvement in all studied features. No adverse effects were reported or detected through laboratory monitoring of mineral metabolism. Conclusion: Topical calcipotriene 0.005% ointment may be an effective treatment for localized Scleroderma, but double-blind placebo controlled studies are needed for confirmation. (J Am Acad Dermatol 1998;39:211-5.)

C. Korkmaz - One of the best experts on this subject based on the ideXlab platform.

Masako Mizoguchi - One of the best experts on this subject based on the ideXlab platform.

  • Linear Scleroderma along Blaschko's lines in a patient with systematized morphea.
    Acta Dermato-venereologica, 2003
    Co-Authors: Yoshinao Soma, Tamihiro Kawakami, Emiko Yamasaki, Rikako Sasaki, Masako Mizoguchi
    Abstract:

    We have previously shown that frontoparietal Scleroderma en coup de sabre, a type of Linear Scleroderma that affects the face and scalp, follows the lines of Blaschko, but the question whether Linear Scleroderma that occurs in the limbs follows Blaschko’s lines has not been answered. We describe the case of a 4-year-old girl with multiple morphea showing remarkable unilateral systematized distribution and whose Linear lesions in the limbs appeared to follow Blaschko’s lines. We suggest that Linear Scleroderma of the limbs, as well as frontoparietal Scleroderma, may occur along the lines of Blaschko. Since both the unilateral distribution and the lesions along Blaschko’s lines are the patterns created by genetic mosaicism, we suggest that a significant part of Linear Scleroderma and perhaps a smaller part of multiple morphea could be related to cutaneous mosaicism. Key words: Blaschko’s lines; systematized morphea; Linear Scleroderma; mosaicism.

  • Linear Scleroderma along Blaschko's lines in a patient with systematized morphea.
    Acta dermato-venereologica, 2003
    Co-Authors: Yoshinao Soma, Tamihiro Kawakami, Emiko Yamasaki, Rikako Sasaki, Masako Mizoguchi
    Abstract:

    We have previously shown that frontoparietal Scleroderma en coup de sabre, a type of Linear Scleroderma that affects the face and scalp, follows the lines of Blaschko, but the question whether Linear Scleroderma that occurs in the limbs follows Blaschko's lines has not been answered. We describe the case of a 4-year-old girl with multiple morphea showing remarkable unilateral systematized distribution and whose Linear lesions in the limbs appeared to follow Blaschko's lines. We suggest that Linear Scleroderma of the limbs, as well as frontoparietal Scleroderma, may occur along the lines of Blaschko. Since both the unilateral distribution and the lesions along Blaschko's lines are the patterns created by genetic mosaicism, we suggest that a significant part of Linear Scleroderma and perhaps a smaller part of multiple morphea could be related to cutaneous mosaicism.

Hermann J. Girschick - One of the best experts on this subject based on the ideXlab platform.

Bari B. Cunningham - One of the best experts on this subject based on the ideXlab platform.

  • topical calcipotriene for morphea Linear Scleroderma
    Journal of The American Academy of Dermatology, 1998
    Co-Authors: Bari B. Cunningham, Ian Landells, Craig B. Langman, Dawn Sailer, Amy S. Paller
    Abstract:

    Abstract Background: Morphea and Linear Scleroderma are characterized by erythema, induration, telangiectasia, and dyspigmentation. There is no universally effective treatment. Oral calcitriol has been beneficial in the treatment of localized and extensive morphea/Scleroderma, but the use of topical calcipotriene has not been reported. Objective: The purpose of this study was to evaluate the efficacy and safety of topical calcipotriene 0.005% ointment in the treatment of localized Scleroderma. Methods: In a 3-month open-label study, 12 patients aged 12 to 38 years with biopsy-documented active morphea or Linear Scleroderma applied calcipotriene ointment under occlusion twice daily to plaques for 3 months. The condition of each patient had previously failed to respond to potent topical corticosteroids and, for some patients, systemic medications. Efficacy was assessed at baseline, 1 month, and 3 months. Levels of serum ionized calcium, intact parathyroid hormone, and 1,25-dihydroxyvitamin D and of random urinary calcium excretion were measured. Results: During the 3-month trial, the condition of all 12 patients showed statistically significant improvement in all studied features. No adverse effects were reported or detected through laboratory monitoring of mineral metabolism. Conclusion: Topical calcipotriene 0.005% ointment may be an effective treatment for localized Scleroderma, but double-blind placebo controlled studies are needed for confirmation. (J Am Acad Dermatol 1998;39:211-5.)

  • Topical calcipotriene for morphea/Linear Scleroderma.
    Journal of the American Academy of Dermatology, 1998
    Co-Authors: Bari B. Cunningham, Ian Landells, Craig B. Langman, Dawn E. Sailer, Amy S. Paller
    Abstract:

    Abstract Background: Morphea and Linear Scleroderma are characterized by erythema, induration, telangiectasia, and dyspigmentation. There is no universally effective treatment. Oral calcitriol has been beneficial in the treatment of localized and extensive morphea/Scleroderma, but the use of topical calcipotriene has not been reported. Objective: The purpose of this study was to evaluate the efficacy and safety of topical calcipotriene 0.005% ointment in the treatment of localized Scleroderma. Methods: In a 3-month open-label study, 12 patients aged 12 to 38 years with biopsy-documented active morphea or Linear Scleroderma applied calcipotriene ointment under occlusion twice daily to plaques for 3 months. The condition of each patient had previously failed to respond to potent topical corticosteroids and, for some patients, systemic medications. Efficacy was assessed at baseline, 1 month, and 3 months. Levels of serum ionized calcium, intact parathyroid hormone, and 1,25-dihydroxyvitamin D and of random urinary calcium excretion were measured. Results: During the 3-month trial, the condition of all 12 patients showed statistically significant improvement in all studied features. No adverse effects were reported or detected through laboratory monitoring of mineral metabolism. Conclusion: Topical calcipotriene 0.005% ointment may be an effective treatment for localized Scleroderma, but double-blind placebo controlled studies are needed for confirmation. (J Am Acad Dermatol 1998;39:211-5.)